TP53 and cancer: Since “normal” cells typically do not expose themselves to the lower fidelity, Topo IIA–dependent controls operating in M-phase and at abscission, then in some cancers where the G2 checkpoint is dysfunctional (e.g., TP53 mutant, discussed above), there are druggable targets that are unusually engaged in these conditional pathways.